Literature DB >> 21873682

Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration.

Hu Huang1, Sara Van de Veire, Mansi Dalal, Rachel Parlier, Richard D Semba, Peter Carmeliet, Stanley A Vinores.   

Abstract

PURPOSE: Prolyl hydroxylases (PHDs) are oxygen sensors that stabilize hypoxia-inducible factors (HIFs) to induce proinflammatory, vasopermeability, and proapoptotic factors. These may be potential targets to reduce the complications of ischemic retinopathies.
METHODS: Oxygen-induced ischemic retinopathy (OIR) was generated as a model for retinopathy of prematurity (ROP) by placing 7-day-old mice in 75% oxygen for 5 days and returning them to the relative hypoxia of room air for 5 days. Neovascularization (NV) and avascular areas were assessed on retinal flat-mounts by image analysis. Blood-retinal barrier breakdown was assessed using ³H-mannitol as a tracer. Apoptosis was detected with TUNEL staining. HIF-1α and VEGF were quantified using Western blot analysis and ELISA.
RESULTS: PHD1-deficient mice demonstrated reduced hyperoxia-associated vascular obliteration during oxygen-induced ischemic retinopathy. This was associated with subsequent reduced avascularity, vascular leakage, and pathologic NV during the hypoxic phase, which could be accounted for by a reduced expression of HIF-1α and VEGF. Apoptosis in the retina was also reduced in PHD1-depleted mice after 2 days in hyperoxia.
CONCLUSIONS: PHD1 deficiency is associated with a reduction of ischemia-induced retinal NV. The regulatory mechanism in this model appears to be: PHD1 depletion prevents HIF-1α degradation in hyperoxia, which induces VEGF, thus preventing hyperoxia-related vessel loss. Without a vessel deficiency, there would not be relative hypoxia when the mice are returned to room air and there would be no need to initiate angiogenesis signaling. Blocking PHD1 may be beneficial for ischemic retinopathies and inflammatory and neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873682      PMCID: PMC3183980          DOI: 10.1167/iovs.11-8002

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  47 in total

1.  Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

Authors:  H P Gerber; F Condorelli; J Park; N Ferrara
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

Review 2.  Oxidative damage to RNA: mechanisms, consequences, and diseases.

Authors:  Qiongman Kong; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2010-02-11       Impact factor: 9.261

3.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha.

Authors:  N V Iyer; L E Kotch; F Agani; S W Leung; E Laughner; R H Wenger; M Gassmann; J D Gearhart; A M Lawler; A Y Yu; G L Semenza
Journal:  Genes Dev       Date:  1998-01-15       Impact factor: 11.361

4.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.

Authors:  J A Forsythe; B H Jiang; N V Iyer; F Agani; S W Leung; R D Koos; G L Semenza
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite.

Authors:  Xiaolin Gu; Azza B El-Remessy; Steven E Brooks; Mohamed Al-Shabrawey; Nai-Tsi Tsai; Ruth B Caldwell
Journal:  Am J Physiol Cell Physiol       Date:  2003-05-07       Impact factor: 4.249

6.  Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.

Authors:  Rebecca J Appelhoff; Ya-Min Tian; Raju R Raval; Helen Turley; Adrian L Harris; Christopher W Pugh; Peter J Ratcliffe; Jonathan M Gleadle
Journal:  J Biol Chem       Date:  2004-07-07       Impact factor: 5.157

Review 7.  HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs.

Authors:  Nathalie M Mazure; M Christiane Brahimi-Horn; Mélanie A Berta; Emmanuel Benizri; Rebecca L Bilton; Frédéric Dayan; Amandine Ginouvès; Edurne Berra; Jacques Pouysségur
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

8.  Quantitative assessment of the integrity of the blood-retinal barrier in mice.

Authors:  Nancy L Derevjanik; Stanley A Vinores; Wei-Hong Xiao; Keisuke Mori; Tara Turon; Tyler Hudish; Steve Dong; Peter A Campochiaro
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

9.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

10.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

View more
  20 in total

Review 1.  Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases.

Authors:  Vaithinathan Selvaraju; Narasimham L Parinandi; Ram Sudheer Adluri; Joshua W Goldman; Naveed Hussain; Juan A Sanchez; Nilanjana Maulik
Journal:  Antioxid Redox Signal       Date:  2013-10-31       Impact factor: 8.401

2.  The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.

Authors:  Richard L Sidman; Jianxue Li; Matthew Lawrence; Wenzheng Hu; Gary F Musso; Ricardo J Giordano; Marina Cardó-Vila; Renata Pasqualini; Wadih Arap
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

3.  The PHD1 oxygen sensor in health and disease.

Authors:  Kilian B Kennel; Julius Burmeister; Martin Schneider; Cormac T Taylor
Journal:  J Physiol       Date:  2018-03-05       Impact factor: 5.182

Review 4.  Balancing the risks and benefits of oxygen therapy in critically III adults.

Authors:  G R Scott Budinger; Gökhan M Mutlu
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

5.  Diacylglycerol kinase (DGK) inhibitor II (R59949) could suppress retinal neovascularization and protect retinal astrocytes in an oxygen-induced retinopathy model.

Authors:  Lu Yang; Yue Xu; Weihua Li; Boyu Yang; Shanshan Yu; Huanjiao Zhou; Cheng Yang; Fan Xu; Jun Wang; Yi Gao; Yongsheng Huang; Lin Lu; Xiaoling Liang
Journal:  J Mol Neurosci       Date:  2014-12-02       Impact factor: 3.444

6.  MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy.

Authors:  Zhenhua Xu; Junsong Gong; Debasish Maiti; Linh Vong; Lijuan Wu; John J Schwarz; Elia J Duh
Journal:  Am J Pathol       Date:  2012-04-19       Impact factor: 4.307

7.  The role of the hypoxia response in shaping retinal vascular development in the absence of Norrin/Frizzled4 signaling.

Authors:  Amir Rattner; Yanshu Wang; Yulian Zhou; John Williams; Jeremy Nathans
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-20       Impact factor: 4.799

8.  Impacts of hypoxia-inducible factor-1 knockout in the retinal pigment epithelium on choroidal neovascularization.

Authors:  Mingkai Lin; Yang Hu; Ying Chen; Kevin K Zhou; Ji Jin; Meili Zhu; Yun-Zheng Le; Jian Ge; Jian-Xing Ma
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-14       Impact factor: 4.799

9.  Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.

Authors:  Amani A Fawzi; Jonathan C Chou; Gina A Kim; Stuart D Rollins; Joann M Taylor; Kathryn N Farrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

Review 10.  The progress of prophylactic treatment in retinopathy of prematurity.

Authors:  Hong-Bing Zhang; Xiao-Dong Wang; Kun Xu; Xiao-Gang Li
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.